TTTakahiro Tsushima

Takahiro Tsushima

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takahiro Tsushima has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardiac Resynchronization Therapy and Conduction System Pacing

    by Thomas Garvey O’neill, Takahiro Tsushima, Bhupendar Tayal

    Left bundle branch block (LBBB), initially described in the early 20th century, has become increasingly recognized as one of the leading causes of advanced heart failure (HF). In addition to rapidly growing data on guideline-directed medical therapy, cardiac resynchronization therapy (CRT) via transvenous coronary sinus lead has been the gold-standard therapy, but one-third of the indicated patients do not receive the expected benefits. Recently, cardiac conduction system pacing (CSP) was identified as an alternative to traditional CRT strategy, and multiple data have been published during the last few years. This review will discuss the diagnostic criteria of LBBB and its relation to the development of HF and review available data for traditional CRT as well as CSP in depth.


  • Open Access

    Beta-blocker initiation under dobutamine infusion in acute advanced heart failure: a target trial emulation with observational data

    by Yuichiro Mori, Kosuke Inoue, Hiroyuki Sato, Takahiro Tsushima, Shingo Fukuma

    In patients with advanced heart failure requiring dobutamine infusion, it is usually recommended to initiate beta-blockers after weaning from dobutamine. However, beta-blockers are sometimes initiated under dobutamine infusion in a real-world scenario. The association between such early beta-blocker initiation with clinical outcomes is unknown. Therefore, this study investigates the association between initiating beta-blockers under dobutamine infusion and survival outcomes. This observational study with a multicentre inpatient-care database emulated a pragmatic randomized controlled trial (RCT) of the beta-blocker initiation strategy. First, 1151 patients on dobutamine and not on beta-blockers on the day of heart failure admission (Day 0) were identified. Among 1095 who met eligibility criteria, patients who were eventually initiated beta-blockers under dobutamine infusion by Day 7 (early initiation strategy) were 1:1 matched to those who were not initiated (conservative strategy). The methods of cloning, censoring, and weighting were applied to emulate the target trial. Patients were followed up for up to 30 days. The primary outcome was all-cause death. Among 780 matched patients (median age, 81 years), the adjusted hazard ratio was 1.11 (95% confidence interval 0.75–1.64, P = 0.59) for the early initiation strategy. The estimated 30-day all-cause mortalities in the early initiation strategy and the conservative strategy were 19.3% (10.6–30.7) and 16.2% (9.2–25.3), respectively. The results were consistent when we used different days to determine strategies (i.e. 5 and 9) instead of 7 days. The present observational study emulating a pragmatic RCT found no positive or negative association between beta-blocker initiation under dobutamine infusion and overall survival. In a panel of patient identification, ‘strategy’ indicates the eventual clinical courses that patients actually followed. In the target trial emulation, all matched patients were cloned into two replicates and assigned to both treatment strategies. Then, they were artificially censored when they deviated from assigned strategies. CI, confidence interval; HR, hazard ratio; IPCW, inverse probability of censoring weighting; RCT, randomized controlled trial.


  • Open Access

    Clinical impact of right ventricular pacing burden in patients with post-transcatheter aortic valve replacement permanent pacemaker implantation

    by Takahiro Tsushima, Sadeer Al-Kindi, Luis Augusto Palma Dallan, Anas Fares, Sung-Han Yoon, Heather L Wheat, Guilherme F Attizzani, Cristian R Baeza, Marc P Pelletier, Mauricio S Arruda, et al.

    Patients who undergo permanent pacemaker (PPM) implantation after transcatheter aortic valve replacement (TAVR) have a worse outcome. The aim of this study was to identify risk factors of worse outcomes in patients with post-TAVR PPM implantation. This is a single-centre, retrospective study of consecutive patients who underwent post-TAVR PPM implantation from 11 March 2011 to 9 November 2019. Clinical outcomes were evaluated by landmark analysis with cut-off at 1 year after the PPM implantation. Of the 1389 patients underwent TAVR during the study duration and a total of 110 patients were included in the final analysis. Right ventricular pacing burden (RVPB) ≥ 30% at 1 year was associated with a higher likelihood of heart failure (HF) readmission [adjusted hazard ratio (aHR): 6.333; 95% confidence interval [CI]: 1.417–28.311; P = 0.016] and composite endpoint of overall death and/or HF (aHR: 2.453; 95% CI: 1.040–5.786; P = 0.040). The RVPB ≥30% at 1 year was associated with higher atrial fibrillation burden (24.1 ± 40.6% vs. 1.2 ± 5.3%; P = 0.013) and a decrease in left ventricular ejection fraction (−5.0 ± 9.8% vs. + 1.1 ± 7.9%; P = 0.005). The predicting factors of the RVPB ≥30% at 1 year were the presence of RVPB ≥40% at 1 month and the valve implantation depth measured from non-coronary cusp ≥4.0 mm (aHR: 57.808; 95% CI: 12.489–267.584; P < 0.001 and aHR: 6.817; 95% CI: 1.829–25.402; P = 0.004). The RVPB ≥30% at 1 year was associated with worse outcomes. Clinical benefit of minimal RV pacing algorithms and biventricular pacing needs to be investigated.


  • Association between status epilepticus and cardiorespiratory comorbidity in patients with epilepsy: A population-based study

    by Takafumi Kubota, Takahiro Tsushima, Sadeer Al-Kindi, Varun Sundaram, Guadalupe Fernandez-Baca Vaca


  • Risk Stratification of New Persistent Left Bundle Branch Block After Transcatheter Aortic Valve Implantation

    by Takahiro Tsushima, Anthony Main, Sadeer G. Al-Kindi, Luis Augusto Palma Dallan, Heather L. Wheat, Cristian R. Baeza, Marc P. Pelletier, Mauricio S. Arruda, Judith A. Mackall, Sergio G. Thal, et al.


  • Abstract 9562: Prediction of Post-TAVR Pacemaker Implantation Using Machine Learning on Pre-TAVR ECG

    by Jamal Hajjari, Takahiro Tsushima, Scott Janus, Heather Wheat, Cristian R Baeza, Sergio Thal, Guilherme Attizzani, Sadeer Al-Kindi

    Introduction: Transcatheter Aortic Valve Replacement (TAVR) is increasingly performed with a decreasing overall complication rate. The risk of complete heart block requiring pacemaker implant (PPI) remains an important complication. Simple and accurate pre-TAVR risk stratification is essential to identify the patients who are at high risk for PPI. Unfortunately, an accurate risk prediction tool is not established yet. Hypothesis: We hypothesized that a pre-existing “electrical fingerprint” on electrocardiography (ECG) is associated with the need for post-TAVR PPI and that using machine learning (ML) approaches on pre-TAVR ECG can predict the need for post-TAVR PPI. Methods: This is a single-center retrospective study of 1032 patients who underwent TAVR from March 2011 to November 2019 at University Hospitals Cleveland Medical Center. Patients with preexisting cardiac implantable electronic devices were excluded. Pre-TAVR ECGs were obtained within 90 days prior to TAVR and a total of 637 features were extracted using ECG MUSE system (GE Healthcare; Milwaukee, WI). We applied hierarchical clustering on 637 ECG features and explored the incidence of post-TAVR PPI in each cluster. Using supervised machine learning, we trained and tested 25 ML algorithms using 445 ECG features (66:34 train:test split). We explored the accuracy of the best 5 ML algorithms on clinical data alone, 26 pre-TAVR clinical variables+ECG, and ECG alone to predict PPI after TAVR. Analysis was done using R Studio (Vienna, Austria) and Waikato Environment for Knowledge Analysis (WEKA, NZ). Results: Hierarchical clustering identified two distinct clusters (cluster 1 has 69% of the patient and cluster has 31% of the patient). The incidence of PPI was 13% in cluster 1 and 33% in cluster 2 (PConclusions: A pre-existing “electrical fingerprint” accounts for significant variation in post-TAVR PPM implant. Unsupervised and supervised ML approaches can be helpful in predicting PPI without the need for inclusion of clinical data. ML-based models can be broadly applied to automatically-extracted ECG features with minimal data preparation


  • Advanced Cardiac Life Support Algorithms—Reply

    by Takahiro Tsushima, Toral R. Patel, Jayakumar Sahadevan

    In Reply We appreciate the insightful comments by Gallen et al in response to our article.1 We would like to thank JAMA Internal Medicine for the opportunity to respond to them. In their letter, Gallen et al comment on the possibility that transcutaneous pacing (TCP) could temporize the decompensated hemodynamics due to significant bradyarrhythmia. Traditionally, the efficacy of TCP for bradyarrhythmic cardiac arrest was thought to be equally limited in both prehospital and inpatient settings.2 In the scenario of prehospital cardiac arrest, which is usually not witnessed, chest compression has been shown to be the most important aspect of resuscitation, and TCP could potentially divert the focus from the effectiveness of chest compression. Therefore, the conventional adult basic and advanced cardiac life support (ACLS) guideline does not recommend TCP for patients with bradyarrhythmic cardiac arrest that occurs before hospital admission.3 Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. Err on the side of full disclosure. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details.


  • Machine Learning Algorithms for Prediction of Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement

    by Takahiro Tsushima, Sadeer Al-Kindi, Fahd Nadeem, Guilherme F. Attizzani, Yakov Elgudin, Alan Markowitz, Marco A. Costa, Daniel I. Simon, Mauricio S. Arruda, Judith A. Mackall, et al.


  • Unusual Cause of Cardiac Arrest

    by Takahiro Tsushima, Toral R. Patel, Jayakumar Sahadevan

    A patient in their 40s with a history of remote coronary artery bypass grafting, heart failure with reduced ejection fraction, and poorly controlled insulin-dependent diabetes was admitted to the cardiac intensive care unit with acute decompensated heart failure. The patient’s baseline electrocardiogram (ECG) demonstrated normal sinus rhythm, with normal PR and QRS intervals at 132 and 82 milliseconds, respectively. With poor response to intravenous (IV) diuretics, the patient underwent right heart cardiac catheterization, which demonstrated a low cardiac index, high left ventricular filling pressure, and elevated systemic vascular resistance. The patient’s outpatient use of metoprolol was discontinued, and IV dobutamine (5.0 µg/kg/min) was initiated with continuing aggressive IV diuresis. While defecating on the bedside commode, the patient became lightheaded and unresponsive. The patient’s pulse was barely palpable, and the ECG rhythm showed bradycardia (Figure). Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. Err on the side of full disclosure. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details.